





OPEN ACCESS

STRIKE-HBV: establishing an HBV screening programme in Kilifi, Kenya—challenges, successes and lessons learnt

Louise O Downs ,^{1,2} Oscar Chirro,² Mwanakombo Zaharani,² Benson Safari,² Dorcas Okanda,² George Githinji,^{2,3} Monique I Andersson,^{4,5} Rob Newton,^{6,7} Anthony Etyang,⁸ Nadia Aliyan,⁹ Philippa Clare Matthews ^{10,11}

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/sextrans-2024-056163>).

For numbered affiliations see end of article.

Correspondence to

Dr Louise O Downs, Nuffield Department of Medicine, University of Oxford, Oxford, UK; louise.downs@exeter.ox.ac.uk

NA and PCM are joint senior authors.

Received 5 March 2024
Accepted 8 May 2024

ABSTRACT

Objectives Chronic hepatitis B infection affects 65 million people in the WHO African Region, but only 4.2% of these are diagnosed and 0.2% on treatment. Here, we present a short report describing establishment of a hepatitis B virus (HBV) programme in Kenya. We share experiences, successes and challenges to support development of future programmes.

Methods From March 2023, we began the 'STRIKE-HBV' Study to identify people living with HBV (PLWHB) in Kilifi, Kenya. We employed local staff and provided education and training. Individuals were identified through three routes: (1) we offered free-of-charge HBV testing for all non-pregnant adults attending Kilifi Country Hospital (KCH) outpatient department; (2) we invited PLWHB to reattend for review; and (3) we invited close contacts of PLWHB for screening and vaccination if HBV was negative. All those seropositive for HBV were offered a comprehensive liver health assessment.

Results We have established a framework for HBV screening, assessment and linkage to care in Kilifi. Between March 2023 and March 2024, we collected data for 80 PLWHB, comprising (1) screening of 1862 people of whom 30 were seropositive, (2) enrolment of 38 people known to be living with HBV and (3) testing of 97 close contacts of PLWHB, of whom 12 were positive. Among a limited subset with elastography data, we identified 9 of 59 as having significant fibrosis, and a further 6 people had laboratory aspartate transaminase (AST) to platelet ratio index (APRI) scores in keeping with fibrosis. We encountered challenges including procurement delays for hepatitis B surface antigen testing kits and HBV vaccinations, and issues accessing liver elastography.

Conclusions HBV screening was well received by the Kilifi population, has identified people at risk of liver disease progression and is improving linkage to care and vaccination at KCH. Future HBV programmes in WHO Africa can build on this experience as we work to develop accessible, affordable and acceptable care pathways.

INTRODUCTION

Approximately 65 million people in the WHO African Region (WHO AFRO) are living with chronic hepatitis B infection (CHB)¹; however, only around 4.2% of these people are diagnosed and 0.2% are on treatment.² There is

⇒ Screening for hepatitis B virus (HBV) infection, vaccination for household/sexual contacts and clinical care for those with chronic HBV disease are not available in much of the WHO African Region.

⇒ We describe our experience of establishing HBV screening in a county hospital in Kenya, to provide accessible, affordable and acceptable access to HBV services.

⇒ We have shown that with a robust programme of education, both the local population and healthcare workers are keen to engage with HBV testing. We have outlined mechanisms by which HBV clinical care can be strengthened and advocate that improvements in HBV care should be a priority for Kenya.

therefore an urgent need to scale up hepatitis B virus (HBV) testing programmes throughout the WHO AFRO.

We here focus on a population in Kilifi County on the Kenyan coast. The estimated CHB prevalence in Kenya is 3–5%, although this is based on data from unrepresentative populations³ and may vary significantly by region. In Kenya, HBV testing is not routine or free in many government hospitals, and HBV vaccination was only introduced into the infant expanded programme for immunisation in 2001.⁴ Lack of access to HBV education, prevention, diagnostics and treatment results in a population at risk of individual liver complications and maintains a population reservoir for continued transmission.

Although Kenyan guidelines on the management of CHB currently advocate HBV biomarker measurement including HBV DNA and hepatitis B 'e' antigen,⁵ there is no mechanism to assess viral replication or liver health other than blood tests such as a complete blood count and alanine aminotransferase (ALT) in most settings, and pathways to care are not well established. At Kilifi County Hospital (KCH), people living with HBV (PLWHB) have been



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

To cite: Downs LO, Chirro O, Zaharani M, et al. *Sex Transm Infect* Epub ahead of print: [please include Day Month Year]. doi:10.1136/sextrans-2024-056163

offered nucleos(t)ide analogue (NA) therapy free of charge, usually tenofovir/lamivudine combination therapy, which is accessible through the national HIV treatment programme. Updated WHO guidelines published in March 2024 endorse this dual therapy approach and the inclusive approach to treatment in the absence of access to detailed stratification.⁶

In this short report, we outline the implementation of an opt-in HBV screening and clinical assessment programme through KEMRI-Wellcome Trust Research Programme at KCH (the 'STRIKE-HBV Study'), aiming to describe the implementation framework used, and share challenges and successes along with preliminary results to support the development of future similar community initiatives to tackle HBV infection.

METHODS

Study location and timeline

KCH is a referral hospital servicing an area of 12 000 km² and a population of 1.5 million people. KCH has 300 inpatient beds and sees 193 000 outpatients every year. A small number of PLWHB are currently managed at KCH through the HIV service, but prior to STRIKE-HBV, there has been no active mechanism for case finding, screening of contacts or vaccination. From March 2023, we began recruiting adults living with HBV infection into a clinical research programme. Data were collected using a REDCap database.⁷

Education, training and consent

We presented STRIKE-HBV to the hospital, subcounty and county management teams for sensitisation and approval, and then engaged with the KCH medical team to facilitate a testing space. We employed and trained study staff and conducted hospital healthcare worker (HCW) sensitisation sessions.

Working with the Hepatitis B Foundation,⁸ we developed educational resources in English and Kiswahili (<https://doi.org/10.6084/m9.figshare.c.7114813.v2>) to support information sessions led by fieldworkers in outpatient waiting areas during screening clinics. The flow of the study is shown in [figure 1](#). We undertook group consent for HBV screening supported by individual discussions if needed. For those known to be living with HBV and managed at KCH, the HIV team invited them to an HBV information session and offered the opportunity to join the study.

Recruitment pathways

PLWHB were identified through three routes:

1. We established voluntary free-of-charge HBV screening at KCH outpatient department (OPD), initially once weekly, but increasing to 3 days/week.
2. We invited those known to be living with HBV to attend for reassessment, supported by local HIV services as above.
3. We invited PLWHB to bring their close contacts for hepatitis B surface antigen (HBsAg) testing. We provided liver health assessment for anyone testing HBsAg positive and vaccinated those HBsAg negative.

HBsAg screening

Testing was done using a point-of-care (POC) HBsAg fingerprick test (first using QuickProfile HBsAg kits (LumiQuick Diagnostics, California, USA) and subsequently determine HBsAg 2 (Abbott, USA)). Anyone testing positive for HBsAg had their results discussed privately and provided consent for additional liver health assessment.

Liver health assessment

All PLWHB enrolled in STRIKE-HBV were offered blood tests and a lifestyle questionnaire (<https://doi.org/10.6084/m9.figshare.25714347.v1>). Liver stiffness assessment was undertaken using Fibroscan Mini+ 430 (Echosens, Paris). We calculated APRI scores using the formula: $\frac{AST/AST (ULN)}{Platelets} \times 100$. Aspartate aminotransferase (AST) upper limit of normal (ULN) was taken as 42 IU/L for women and 47 IU/L for men as per local Kilifi reference ranges. Elastography scores >7 kPa and APRI scores >0.5 were considered significant fibrosis. All quantitative analyses were performed using Microsoft Excel V.16.8.

Funding

This project is funded by the Wellcome Trust (grant 225485/Z/22/Z) and the John Fell Fund, University of Oxford (ref: 0012112).

RESULTS

Screening numbers and characteristics

Between March 2023 and March 2024 inclusive, we screened 1862 people for HBV (75% female, median age 41 years, range 18–98 years) and we scaled up testing as the study progressed (online supplemental figures 1 and 2). 30 people were newly tested HBsAg positive (17 female, 13 male, median age 45 years, range 21–86 years). We also enrolled 38 people already living with HBV (25 female, 13 male, median age 34 years, range 25–60 years) and tested 97 household or sexual contacts for HBsAg of whom 12 were also positive (12.4%, 7 female, 5 male, median age 38 years, range 25–55 years).

Liver health assessment

Elastography scores were available for 27 participants newly diagnosed with HBV and 32 participants already known to be living with HBV. Five of 27 and 4 of 32 in each group, respectively, had significant fibrosis based on elastography (prevalence 9 of 59, 15.3%) and a further 6 participants were identified based on APRI score (prevalence 15 of 59, 25.4%).

Positive outcomes of screening

STRIKE-HBV has created awareness around HBV both in the Kilifi population and HCWs at KCH. Often community members attend the clinic based on personal recommendation, and attended to seek information, support and referral for care. Five education sessions have been held for hospital staff and have been well received (<https://doi.org/10.6084/m9.figshare.25526284.v1>). As a result of this work, KCH is in the process of undertaking free HBV vaccination for all HCWs (<https://doi.org/10.6084/m9.figshare.25718268>) and the current HBV clinical care service is developing a peer support network for PLWHB.

Challenges initiating the programme

- *Procurement issues:* we used a combination of HBsAg testing kits because of significant delays due to central and local distributor issues, manufacturing and importation time.
- *Elastography measurement:* this was delayed while negotiating access to hardware. Purchasing a new or secondhand machine was prohibitively expensive, so we organised a loan machine which only became available 10 months after study initiation.
- *Vaccination:* obtaining monovalent HBV vaccination was challenging due to national stock issues and then delivery without temperature monitoring. Eventually, single-dose




Figure 1 Flow of the STRIKE-HBV Study—a cross-sectional study recruiting outpatients attending Kilifi County Hospital (KCH), Kenya to undertake hepatitis B surface antigen (HBsAg) testing, liver health assessment, referral to clinical care, tracing and vaccination of close contacts. Inclusion criteria are shown along with investigations undertaken on those testing HBsAg positive, referral and vaccination pathways. ALT, alanine aminotransferase; AST, aspartate aminotransferase; bHCG, beta-human chorionic gonadotropin; GGT, gamma-glutamyl transpeptidase; Hb, haemoglobin; HBeAg, hepatitis B 'e' antigen; HBV, hepatitis B virus; INR, international normalised ratio; kPa, kilopascals; OPD, outpatient department.

vaccine vials were obtained, but at significantly higher cost than multidose vials.

- **Screening capacity:** scale-up was limited by location and availability of clinic space and number of staff.

DISCUSSION

Our approach to establishing an HBV programme in a county hospital in Kenya demonstrates that with appropriate support and education, screening for HBV and referral to clinical care are feasible and acceptable and identify people with liver disease requiring NA therapy to prevent further disease progression. A high proportion of the people we tested were women due to the demographic of those attending KCH. The lower engagement of men is concerning given their higher risk of HBV and related liver complications.^{9,10} Expansion of testing into communities may improve screening coverage, but also education targeting men specifically may be needed.

HBsAg POC tests well validated in African populations⁸ are expensive and difficult to access, sometimes meaning less well-validated tests are used. Elastography machines are not easily available; however, recent WHO guidelines advocate the use of APRI scores.⁶ Vaccine access was consistently challenging, highlighting the need for government and global commitment to ensure consistent, equitable supply of vaccines.

When project recruitment is complete, we will undertake standardisation of data in our OPD population for age and sex against the Kilifi population structure to enable HBV prevalence estimation. Cost-effectiveness of such programmes requires careful evaluation, considering the short-term resource implications of scale-up, offset by long-term gains in population health. Simplified WHO guidelines⁶ reduce the cost implications of stratification for treatment, setting the scene for a scale-up of interventions.

CONCLUSIONS

HBV screening in KCH was well received and identified people with liver disease. People already diagnosed but not engaged in care were linked into the HIV clinic for ongoing management. Scale-up of this programme is needed to allow increased screening availability while balancing affordability and acceptability.

Author affiliations

- ¹Nuffield Department of Medicine, University of Oxford, Oxford, UK
- ²KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- ³Department of Biochemistry and Biotechnology, Pwani University, Kilifi, Kenya
- ⁴Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- ⁵Radcliffe Department of Medicine, University of Oxford, Oxford, UK
- ⁶Uganda Virus Research Institute, Entebbe, Wakiso, Uganda
- ⁷Department of Health Sciences, University of York, York, UK
- ⁸Epidemiology and Demography, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- ⁹Kilifi District Hospital, Kilifi, Kenya
- ¹⁰The Francis Crick Institute, London, UK
- ¹¹Division of Infection and Immunity, University College London, London, UK

Handling editor Mark Charles Atkins

X Louise O Downs @lou_downs and Philippa Clare Matthews @pippa_matt

Acknowledgements We would like to thank all the staff at Kilifi County Hospital for their cooperation and assistance during the undertaking of the STRIKE-HBV

Study. They have been helpful in ways that are above and beyond their duty. In particular the medical superintendent Dr Malik-ul-Ashtar and the team at the maternal child health facilities and adult outpatient department. This manuscript was written with the permission of the director of KEMRI CGMRC.

Contributors Study concept and manuscript writing—LOD, OC, MZ, BS, PCM, NA, GG, AE and RN. Study team—OC, MZ, BS, DO and LOD. Data analysis and interpretation—LOD, PCM, NA, RN and DO. Writing assistance—LOD, PCM, MIA, AE, NA and GG. Proofreading the article—all authors.

Funding This research was funded in whole or in part by the Wellcome Trust (grant number 225485/Z/22/Z). For the purpose of Open Access, the author has applied a CC-BY public copyright license to any author accepted manuscript version arising from this submission. LOD is funded by a Wellcome Trust Grant (number 225485/Z/22/Z) and Oxford University John Fell Fund (award number 0012112). PCM is supported by a Wellcome fellowship (ref 110110/Z/15/Z).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the Scientific and Ethics Review Unity (SERU), Kenya (number 4656) and Oxford Tropical Research Ethics Committee (Oxtrec) (number 22-23). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Louise O Downs <http://orcid.org/0000-0002-6088-4704>
 Philippa Clare Matthews <http://orcid.org/0000-0002-4036-4269>

REFERENCES

- 1 Global progress report on HIV, viral hepatitis and sexually transmitted infections. *Accountability for the Global Health Sector Strategies 2016–2021: Actions for Impact*. Genève, Switzerland: World Health Organization, 2021:112.
- 2 Global hepatitis programme. n.d. Available: <https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/overview>
- 3 Downs LO, Campbell C, Yonga P, et al. A systematic review of hepatitis B virus (HBV) prevalence and Genotypes in Kenya: data to inform clinical care and health policy. *PLOS Glob Public Health* 2023;3:e0001165.
- 4 Kenyan Ministry for Health. Kenyan Ministry for health guidelines Immunisation.Pdf. 2023.
- 5 Guidelines,standards & policies portal. n.d. Available: <http://guidelines.health.go.ke/#/category/10/29/meta>
- 6 Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. World Health Organization; 2024. Available: <https://www.who.int/publications/i/item/9789240090903>
- 7 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (Redcap)—a Metadata-driven methodology and Workflow process for providing Translational research Informatics support. *J Biomed Inform* 2009;42:377–81.
- 8 Home » hepatitis B foundation. 2023. Available: <https://www.hepb.org/>
- 9 Wu J-F, Song S-H, Lee C-S, et al. Clinical predictors of liver fibrosis in patients with chronic hepatitis B virus infection from children to adults. *J Infect Dis* 2018;217:1408–16.
- 10 Ramirez Mena A, Ngom NF, Tine J, et al. Prevalence and predictors of liver fibrosis in people living with hepatitis B in Senegal. *Viruses* 2022;14.